

Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Wednesday 20 March 2019, 10:12 to 16:35

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:

1. Professor Gary McVeigh (Chair)	Present for all notes
2. Dr Lindsay Smith (Vice Chair)	Present for all notes
3. James Avery	Present for all notes
4. Nabeel Alsindi	Present for all notes
5. Professor David Bowen	Present for all notes
6. Professor Rachel Elliott	Present for all notes
7. Gillian Ells	Present for all notes
8. Professor Paula Ghaneh	Present for all notes
9. Rebecca Harmston	Present for all notes
10. Dr Andrew Hitchings	Present for all notes
11. Dr Bernard Khoo	Present for all notes
12. Dr Soo Fon Lim	Present for all notes
13. Dr Guy Makin	Present for all notes
14. Professor David Meads	Present for all notes
15. Olaolu Oloyede	Present for all notes
16. Dr Malcolm Oswald	Present for all notes

In attendance:

Lazaros Andronis	Project lead, ERG representative, Warwick Evidence	Present for notes 18 to 19
Peter August	Project Health Economist, ERG representative, Warwick Evidence	Present for notes 18 to 19
Gemma Barnacle	Project Manager, National Institute for Health and Care Excellence	Present for notes 1 to 17
Rebecca Bouch	Administrator, National Institute for Health and Care Excellence	Present for all notes
Professor Peter Clark	CDF Clinical Lead, NHS England	Present for all notes

Luke Cowie	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 18 to 22
Carol Davies	Patient expert, y nominated National Lung Cancer Forum for Nurses	Present for notes 5 to 13 and 18 to 19.
Henry Edwards	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 1 to 31
Joanne Ekeledo	Project Manager, National Institute for Health and Care Excellence	Present for notes 18 to 22
Dr Carles Escriu	Clinical Expert, nominated by AstraZeneca	Present for notes 5 to 13
Nigel Fleeman	Research Fellow, ERG representative, Liverpool Reviews and Implementation Group (LRiG)	Present for notes 5 to 13
Daniel Gallacher	Project Statistician, ERG representative, Warwick Evidence	Present for notes 18 to 19
Dr Alistair Greystoke	Clinical Expert, nominated by AstraZeneca	Present for notes 5 to 13 and 18 to 19
Christian Griffiths	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 1 to 17
Nicola Hay	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 1 to 22
Rachel Houten	ERG representative, Liverpool Reviews and Implementation Group (LRiG)	Present for notes 5 to 13
Caron Jones	Technical Advisor, National Institute for Health and Care	Present for notes 23 to 33

Excellence

Gavin Kenny	Assistant Project Manager, National Institute for Health and Care Excellence	Present for all notes
Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Tosin Lambe	ERG representative, Liverpool Reviews and Implementation Group (LRiG)	Present for notes 5 to 13
Linda Landells	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Joanne Lord	ERG representative, Southampton Health Technology Assessment Centre (SHTAC)	Present for notes 23 to 30
James Maskrey	Project Manager, National Institute for Health and Care Excellence	Present for notes 23 to 34
Stephen Robinson	Technical Analyst, National Institute for Health and Clinical Excellence	Present for notes 1 to 17
Jonathan Shepherd	ERG representative, Southampton Health Technology Assessment Centre (SHTAC)	Present for notes 23 to 30
Emily Eaton Turner	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 23 to 33
Non-public attendees:		
Helen Crosbie	Public Involvement Advisor, National Institute for Health and Care Excellence	Present for notes all notes
Ann Greenwood	Editor, National Institute for Health and Care	Present for notes all notes

Excellence

Mary Jordan	Evidence Review Group member, Warwick Evidence	Present for notes all notes
Alan Moore	Technical Analyst, National Institute for Health and Care Excellence	Present for notes all notes
Madeleine Still	NIHRIO	Present for notes all notes
Ying Ying Wang	Technical Analyst, National Institute for Health and Care Excellence	Present for notes all notes
Maroulla Whiteley	Costing Lead, National Institute for Health and Care Excellence	Present for notes all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302], dacomitinib for untreated EGFR-positive non-small-cell lung cancer [ID1346] and atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210].
2. The Chair informed the Committee of the non-public observers at this meeting: Helen Crosbie, Ann Greenwood, Mary Jordan, Alan Moore, Madeleine Still, Ying Ying Wang and Maroulla Whiteley
3. Apologies were received from Dr Peter Hall, Dr Robert Hodgson, Libby Mills and Dr Paula Parvulescu.

Any other Business

4. None.

Appraisal of Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]

Part 1 – Open session

5. The Chair welcomed the invited experts: Carol Davies, Peter Clark, Dr Carles Escriu and Alistair Greystoke to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from AstraZeneca UK Ltd to the meeting.
7. The Chair asked all Committee members to declare any relevant interests Dr Lindsay Smith (Vice Chair), James Avery, Nabeel Alsindi, Professor David Bowen, Professor Rachel Elliott, Gillian Ells, Professor Paula Ghaneh, Rebecca Harmston, Dr Andrew Hitchings, Dr Bernard Khoo, Dr Soo Fon Lim, Dr Guy Makin, Professor David Meads, Olaolu Oloyede, Dr Malcolm Oswald all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302].
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302].

9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. Dr Carles Escriu declared that he had received payment from AstraZeneca for lecturing and also received grants from AstraZeneca for research.
 - 9.1.1. It was agreed that this declaration would not prevent Dr Escriu from participating in this section of the meeting
 - 9.2. Dr Alistair Greystoke declared that he had received speaker and consultancy fees from AstraZeneca, Pfizer, Roche and Boehringer.
 - 9.2.1. It was agreed that this declaration would not prevent Dr Greystoke from participating in this section of the meeting
 - 9.3. Carol Davies declared that the National Lung Cancer Forum for Nurses (NLCFN) had received educational sponsorship from pharmaceutical companies.
 - 9.3.1. It was agreed that this declaration would not prevent Carol Davies from participating in this section of the meeting
10. The Chair introduced the lead team, Gillian Ells, Malcolm Oswald and Rachel Elliott who gave presentations on the clinical effectiveness and cost effectiveness of osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302].
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. The committee discussed confidential information submitted by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302].
 - 15.1. The committee decision was based on consensus.
16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
17. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Appraisal of Dacomitinib for untreated EGFR-positive non-small-cell lung cancer [ID1346]

Part 1 – Open session

18. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Pfizer.
19. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
 - 19.1. Dr Alistair Greystoke declared that he had received speaker and consultancy fees from AstraZeneca, Pfizer, Roche and Boehringer.
 - 19.1.1. It was agreed that this declaration would not prevent Dr Greystoke from participating in this section of the meeting
 - 19.2. Carol Davies declared that the National Lung Cancer Forum for Nurses (NLCFN) had received educational sponsorship from pharmaceutical companies.
 - 19.2.1. It was agreed that this declaration would not prevent Carol Davies from participating in this section of the meeting
 - 19.3. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session

20. The committee discussed confidential information submitted by the company.
21. The Committee continued to discuss the clinical and cost effectiveness of dacomitinib for untreated EGFR-positive non-small-cell lung cancer [ID1346].
22. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210]

Part 1 – Open session

23. The Chair welcomed company representatives from Roche Products to the meeting.
24. The Chair asked all Committee members to declare any relevant interests The Chair asked all Committee members to declare any relevant interests Dr Lindsay Smith (Vice Chair), James Avery, Nabeel Alsindi, Professor David Bowen, Professor Rachel Elliott, Gillian Ells, Professor Paula Ghaneh, Rebecca Harmston, Dr Andrew Hitchings, Dr Bernard Khoo, Dr Soo Fon Lim, Dr Guy Makin, Professor David Meads, Olaolu Oloyede, Dr Malcolm Oswald all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210].

25. The Chair asked all NICE Staff to declare any relevant interests.
 - 25.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210].
26. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 26.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210]
27. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
28. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
29. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
30. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

31. Discussion on confidential information continued. This information was supplied by the company.
32. The Committee continued to discuss the clinical and cost effectiveness of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210].
 - 32.1. The committee decision was based on consensus.
33. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

34. Tuesday 16 April 10:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.